New technique stabilizes siRNAs without affecting gene silencing ability
Credit: Danielle Vlaho, Johans F. Fakhoury, and Masad J. Damha. siRNA molecules modified with phosphoramidate linkages
Researchers have reported the ability to modify the structure of small interfering RNAs (siRNAs) to improve their stability and therapeutic potential without negatively affecting their potency and ability to silence targeted genes. The oligonucleotide modifications used and the experimental measures of thermal stability, helical structure, and gene expression are described in an article published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
The article entitled “Structural Studies and Gene Silencing Activity of siRNAs Containing Cationic Phosphoramidate Linkages” is coauthored by Danielle Vlaho, Johans Fakhoury, and Masad Damha, McGill University, Montreal, Canada. They provide a detailed description of the phosphoramidate modifications introduced in either siRNA passenger or guide strands to overcome stability issues and they detail any negative effects on the biological properties of the modified siRNAs.
"The ability to enhance siRNA stability and improve uptake by introducing internucleotide linkage phosphoramidate modifications into oligonucleotides is an important advance to achieve stability without sacrificing potency," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019